Brief: Gamida Cell Announces FDA Clearance Of IND And Removal Of Clinical Hold For NK Cell Therapy Candidate Gda-201
26/04/2022 12:09
April 26 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL ANNOUNCES FDA CLEARANCE OF IND AND REMOVAL OF CLINICAL HOLD
FOR NK
CELL THERAPY CANDIDATE GDA-201
* GAMIDA CELL LTD - ADVANCING PLANS TO BEGIN PHASE 1/2 STUDY IN PATIENTS
WITH
FOLLICULAR AND DIFFUSE LARGE B-CELL LYMPHOMAS
* GAMIDA CELL - EXPECTS TO INITIATE A COMPANY-SPONSORED PHASE 1/2 CLINICAL
STUDY
IN PATIENTS WITH FOLLICULAR AND DIFFUSE LARGE B-CELL LYMPHOMAS IN 2022
Source text for Eikon: ID:nBw1cXy94a
Further company coverage: GMDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq